logo
ENFRع
#

Latest news with #SunPharma

Sun Pharma Share Price Live Updates: Sun Pharma's recent performance shows a bearish crossover
Sun Pharma Share Price Live Updates: Sun Pharma's recent performance shows a bearish crossover

Time of India

timea day ago

  • Business
  • Time of India

Sun Pharma Share Price Live Updates: Sun Pharma's recent performance shows a bearish crossover

Stay informed with the Sun Pharma Stock Liveblog, your comprehensive resource for real-time updates and in-depth analysis of a leading stock. Get the latest details on Sun Pharma, including: Last traded price 1672.1, Market capitalization: 403712.1, Volume: 65210, Price-to-earnings ratio 36.83, Earnings per share 45.55. Our liveblog combines fundamental and technical insights to provide a holistic view of Sun Pharma's performance. Stay ahead of the market with breaking news that can influence Sun Pharma's trajectory. Our expert analysis and stock recommendations empower you to make well-informed financial decisions. Trust the Sun Pharma Stock Liveblog for up-to-date information and expert insights. The data points are updated as on 09:46:21 AM IST, 23 Jul 2025 Show more Show less

Sun Pharma's ILUMYA delivers positive psoriatic arthritis trial results
Sun Pharma's ILUMYA delivers positive psoriatic arthritis trial results

Business Standard

time3 days ago

  • Health
  • Business Standard

Sun Pharma's ILUMYA delivers positive psoriatic arthritis trial results

Sun Pharmaceutical Industries has announced that its psoriasis drug ILUMYA (tildrakizumab 100 mg) delivered positive results in two late-stage clinical trials for active psoriatic arthritis (PsA), potentially paving the way for regulatory filings in the United States. The Phase 3 INSPIRE-1 and INSPIRE-2 studies evaluated the efficacy and safety of ILUMYA over a 24-week period. According to the company, both trials achieved statistically significant improvements in ACR20 response rates—a standard measure of arthritis treatment effectiveness—compared with placebo at Week 24. INSPIRE-1 included patients with prior exposure to anti-TNF therapies, while INSPIRE-2 focused on anti-TNF naïve patients. More than 800 adult participants were enrolled across clinical sites in the US, Europe, and Asia. ILUMYA was administered at Week 0 and every 12 weeks thereafter, with no induction dose. Consistent safety profile supports regulatory case Sun Pharma stated that the safety outcomes in the psoriatic arthritis trials were consistent with ILUMYA's established safety profile from earlier studies in plaque psoriasis. No new safety signals were identified. ILUMYA is currently approved in the US and other countries for the treatment of moderate-to-severe plaque psoriasis in adults. Its use in psoriatic arthritis remains investigational and has not yet been evaluated by regulatory authorities. Detailed results from the INSPIRE studies will be presented at upcoming medical conferences and submitted for publication in peer-reviewed journals. Targeting IL-23 in chronic inflammatory pathways ILUMYA is a monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), thereby inhibiting inflammatory pathways associated with chronic autoimmune conditions. Common adverse reactions reported in previous studies include upper respiratory infections, injection-site reactions, and diarrhoea. The drug carries warnings related to hypersensitivity, infections, and tuberculosis risk. Psoriatic arthritis affects an estimated 2.4 million people in the United States. Approximately one-third of psoriasis patients may develop the joint condition, though many cases remain undiagnosed. Strategic pipeline strengthens global presence Sun Pharma is India's largest pharmaceutical company and one of the world's leading generic drug manufacturers. The company operates in over 100 countries and has a growing specialty portfolio in dermatology, ophthalmology, and onco-dermatology.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store